Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 19

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 19
---
 liabilities 
     (220)
  
    Long-term operating lease liabilities 
    $231 

  Weighted-average remaining lease term   1.8 years           Weighted-average discount rate   12.0% 

During the three and six months ended June 30, 2025 the Company recognized
$55,000 and $95,000, respectively, in operating lease expense, which is included in general and administrative expenses in the Company’s
consolidated statement of operations.

During the three and six months ended June 30,
2024, the Company recognized $41,000 and $80,000, respectively, in operating lease expense, which is included in general and administrative
expenses in the Company’s consolidated statement of operations

During April 2025, the Company’s wholly-owned subsidiary, INmune Bio International. Ltd., entered into a 2-year collaboration agreement
with a vendor whereby it shall make fixed payments to the vendor in exchange for services pursuant to manufacturing CORDStrom in the United
Kingdom. A summary of the commitments payable for these services pursuant to the agreement is as follows as of June 30, 2025:

    (in thousands, except years) 

    2025 
    $532 
  
    2026 
     1,285 
  
    2027 
     1,152 
  
    Total 
    $2,969 

13

NOTE 7 – RELATED PARTY TRANSACTIONS

UCL

At June
30, 2025 and December 31, 2024, the Company recorded a payable to UCL of $133,000 and $0, respectively, for medical research performed
on behalf of the Company. During the six months ended June 30, 2025 and 2024, the Company made no payments to UCL. UCL is a wholly owned
subsidiary of the University of London. The Company’s Chief Scientific and Manufacturing Officer is a professor at the University
of London.

AmplifyBio

At June
30, 2025 and December 31, 2024, the Company recorded a payable to AmplifyBio of $26,000 and $0, respectively, for medical research performed
on behalf of the Company. During the six months ended June 30, 2025 and 2024, the Company paid AmplifyBio $41,000 and $233,000, respectively